Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement - Scorecard - MDSpire
Advertisement
Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement
Clinical Scorecard: Clinical Case Study: Alectinib and CNS-targeted Treatment for Primary or Recurrent ALK-positive Anaplastic Large Cell Lymphoma with Central Nervous System Involvement
At a Glance
Category
Detail
Condition
ALK-positive anaplastic large cell lymphoma (ALCL) with CNS involvement; a rare T-cell lymphoma with poor prognosis in CNS cases.
Key Mechanisms
Involves ALK gene fusions leading to oncogenic activity; treatment with ALK inhibitors like alectinib shows promise in CNS involvement.
Target Population
Patients with ALK-positive ALCL, particularly those with CNS involvement, including young adults.
Care Setting
Oncology, specifically for patients with relapsed or refractory ALK-positive ALCL, requiring multidisciplinary management.
Key Highlights
ALK-positive ALCL is a rare T-cell lymphoma with a generally favorable prognosis but poor outcomes in CNS involvement.
Alectinib, an ALK inhibitor, shows efficacy in treating CNS involvement in ALK-positive ALCL, as demonstrated in two case studies.
Case 1: 18-year-old male achieved CNS remission after alectinib and HSCT; Case 2: 31-year-old female with primary CNS involvement responded well to alectinib.
Guideline-Based Recommendations
Diagnosis
Confirm ALK-positive ALCL through biopsy and genetic testing for ALK fusions.
Management
Consider alectinib for patients with CNS involvement after standard therapies fail; monitor for potential side effects.
Monitoring & Follow-up
Regular imaging (MRI, PET/CT) to assess CNS response and disease progression; include long-term follow-up care.
Risks
CNS involvement is associated with poor prognosis; treatment may involve risks of toxicity and complications from HSCT.
Patient & Prescribing Data
Young adults with ALK-positive ALCL and CNS involvement; consider age and health status.
Alectinib (600 mg twice daily) has shown effectiveness in achieving CNS remission; monitor for side effects.
Clinical Best Practices
Utilize a multidisciplinary approach for managing ALK-positive ALCL with CNS involvement; include oncologists, neurologists, and supportive care.
Monitor for CNS symptoms and disease progression closely in patients with ALK-positive ALCL; establish a follow-up care plan.
by Milda Mikalonytė, Vilhelmas Landsbergis, Lukas Kevličius, Skirmantė Černauskienė, Linas Davainis, Andrius Žučenka, Igoris Trociukas, Regina Pileckytė, Birutė Davainienė, Inga Šlepikienė, Gintarė Ražanskienė, Ugnius Mickys, Jonas Ražanskas, Jūratė Dementavičienė, Mindaugas Stoškus, Raminta Batiuškaitė, Laimonas Griškevičius
